乙拉西坦结构式
|
常用名 | 乙拉西坦 | 英文名 | Etiracetam |
|---|---|---|---|---|
| CAS号 | 33996-58-6 | 分子量 | 170.209 | |
| 密度 | 1.2±0.1 g/cm3 | 沸点 | 395.9±25.0 °C at 760 mmHg | |
| 分子式 | C8H14N2O2 | 熔点 | N/A | |
| MSDS | N/A | 闪点 | 193.2±23.2 °C | |
| 符号 |
GHS07, GHS09 |
信号词 | Warning |
乙拉西坦用途Etiracetam (UCB 6474) 是乙酰胆碱的激动剂,是一种抗精神病药物。活性低于它的S型对映异构体 Levetiracetam (UCB L059)。 |
| 中文名 | 益智酰胺 |
|---|---|
| 英文名 | 2-(2-oxopyrrolidin-1-yl)butanamide |
| 中文别名 | 乙拉西坦 |
| 英文别名 | 更多 |
| 密度 | 1.2±0.1 g/cm3 |
|---|---|
| 沸点 | 395.9±25.0 °C at 760 mmHg |
| 分子式 | C8H14N2O2 |
| 分子量 | 170.209 |
| 闪点 | 193.2±23.2 °C |
| 精确质量 | 170.105530 |
| PSA | 64.39000 |
| LogP | -0.67 |
| InChIKey | HPHUVLMMVZITSG-UHFFFAOYSA-N |
| SMILES | CCC(C(N)=O)N1CCCC1=O |
| 蒸汽压 | 0.0±0.9 mmHg at 25°C |
| 折射率 | 1.519 |
| 储存条件 | 2-8℃ |
| 符号 |
GHS07, GHS09 |
|---|---|
| 信号词 | Warning |
| 危害声明 | H302-H319-H411 |
| 警示性声明 | P273-P305 + P351 + P338 |
| 危害码 (欧洲) | Xn:Harmful; |
| 风险声明 (欧洲) | R22;R36 |
| 安全声明 (欧洲) | S26 |
| 危险品运输编码 | UN 3077 9 / PGIII |
|
Inhibition of excitatory synaptic transmission in hippocampal neurons by levetiracetam involves Zn²⁺-dependent GABA type A receptor-mediated presynaptic modulation.
J. Pharmacol. Exp. Ther. 348(2) , 246-59, (2014) Levetiracetam (LEV) is an antiepileptic drug with a unique but as yet not fully resolved mechanism of action. Therefore, by use of a simplified rat-isolated nerve-bouton preparation, we have investiga... |
|
|
Efficacy and safety of pregabalin versus levetiracetam as adjunctive therapy in patients with partial seizures: a randomized, double-blind, noninferiority trial.
Epilepsia 55(7) , 1048-57, (2014) To assess the comparative efficacy and safety of pregabalin and levetiracetam for the reduction of seizure frequency in patients with partial seizures.This was a randomized, double-blind, flexible-dos... |
|
|
The established status epilepticus trial 2013.
Epilepsia 54 Suppl 6 , 89-92, (2013) Benzodiazepine-refractory status epilepticus (established status epilepticus, ESE) is a relatively common emergency condition with several widely used treatments. There are no controlled, randomized, ... |
| UCB 6474 |
| (±)-a-Ethyl-2-oxo-1-pyrrolidineacetamide |
| ucb L059 |
| T5NVTJ AY2&VZ |
| Etiracetam |
| 2-(2-Oxo-1-pyrrolidinyl)butanamide |
| α-Ethyl-2-oxo-1-pyrrolidineacetamide |
| UNII:230447L0GL |
| Levetiracetam Racemic Mixture |
| 乙拉西坦 |
| 2-(2-Oxopyrrolidin-1-yl)butyramide |
| (±)-α-Ethyl-2-oxo-1-pyrrolidineacetamide |
| 2-(2-oxopyrrolidin-1-yl)butanamide |